Pfizer Inc
Trump tariff fallout: Some industries grapple with lingering effects one year later
A year after President Donald Trump declared his “liberation day” and imposed sweeping tariffs on imports, kicking off a wave of economic and political uncertainty, some companies are still feeling the effects. While some industries have emerged largely unscathed — having weathered twists and turns of several tariff iterations — others, such as retail, automotive, […]
Read More
Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs
The Trump administration is preparing to impose new tariffs on branded drugs from pharmaceutical companies that have not struck landmark deals with the president to lower their U.S. drug prices, CNBC has learned. Patented medications and their active ingredients would be hit with a 100% tariff, according to a draft of the document obtained by […]
Read More
Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison
Wegovy semaglutide tablets. Michael Siluk | Universal Images Group | Getty Images The Wegovy pill showed more pronounced weight loss and less cumbersome side effects than Eli Lilly‘s rival pill that was approved this week, Novo Nordisk said Thursday. Oral Wegovy demonstrated “significantly greater mean weight loss” than orforglipron, which Lilly will sell under the […]
Read More
How Ireland became dependent on big pharma — and the risks ahead
In just 50 years, Ireland has become the world’s third largest exporter of pharmaceuticals, with medicines now making up about 20% of Ireland’s GDP. So how did Ireland become so tied to the pharma industry — and is that reliance at risk amid tariffs, patent cliffs and geopolitical tension? Ireland manufactures some of the world’s […]
Read More
Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss
Thomas Fuller | Nurphoto | Getty Images Pfizer on Monday said it will seek regulatory approval for a Lyme disease vaccine candidate despite the shot failing a late-stage trial. Pfizer said the vaccine missed the trial’s statistical goal because not enough people in the study contracted Lyme disease to be confident in the results. Still, […]
Read More
FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, Copenhagen, Denmark, Feb. 4, 2026. Tom Little | Reuters The Food and Drug Administration on Thursday approved a higher dose version of Novo Nordisk‘s blockbuster weight loss injection Wegovy, as the company pushes to win back market share from […]
Read More
Adobe CEO Shantanu Narayen says he will step down after company installs successor
Adobe said CEO Shantanu Narayen will step down after a successor has been appointed, and he will remain as the design software company’s chair. Shares tumbled 7% in extended trading. Narayen joined Adobe in 1988 as a vice president and general manager, and he became CEO in 2007. Under Narayen, Adobe pushed from software licenses […]
Read More
Iran war: Israel’s president Herzog calls ‘cost’ for business the price for Middle East peace
Israeli President Isaac Herzog visits the site of an Iranian strike in Beit Shemesh, Israel, March 2, 2026. Alexi J. Rosenfeld | Getty Images Israeli President Isaac Herzog told a group of U.S. business leaders at the Yale CEO caucus meeting on Tuesday that he understands their concerns about the costs of the war against […]
Read More
FDA approves leucovorin as first drug for rare genetic disorder, after touting it as autism treatment
FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Maryland November 4, 2009. Jason Reed | Reuters The Food and Drug Administration on Tuesday approved a decades-old prescription vitamin called leucovorin as the first treatment for a rare genetic disorder in certain adults and children. The move […]
Read More
Oil prices top $100, FDA leadership change, the wellness boom and more in Morning Squawk
This is CNBC’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Good morning. If you’re getting on a plane soon, consider this a public service announcement that you may want to give yourself extra time for security lines. Stock futures are tanking this morning following a losing week on Wall Street. Here are […]
Read More